Blackstone Life Sciences Fund
GPTKB entity
Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Investment Fund
|
| gptkbp:establishedIn |
2020
|
| gptkbp:focusesOn |
Life_Sciences_Investments
|
| gptkbp:funding |
$4.6 billion
|
| gptkbp:geographicalFeature |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:headquarteredIn |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Blackstone Life Sciences Fund
|
| gptkbp:investmentFocus |
Collaborative
Growth Stage Acquisitions Gene Therapy Precision Medicine Cell Therapy Early Stage Long-term Value Creation Innovative Therapies Public Offerings Successful Exits Partnerships_with_Corporations Venture_Capital |
| gptkbp:managedBy |
gptkb:Blackstone_Group
|
| gptkbp:notableEvent |
gptkb:Zymeworks
gptkb:Sana_Biotechnology gptkb:Aprea_Therapeutics Freenome AviadoBio |
| gptkbp:partnerships |
Academic Institutions
Research Organizations Pharma Companies Biotech_Companies |
| gptkbp:performance |
IRR
Multiple_on_Invested_Capital |
| gptkbp:regulatoryCompliance |
Clinical Trials
Market Access FDA_Approval |
| gptkbp:targets |
Biotechnology
Medical Devices Pharmaceuticals Healthcare_Services |
| gptkbp:teamAchievements |
Industry Experts
Scientific Advisors Experienced Investors |